DekaBank Deutsche Girozentrale Sells 5,826 Shares of Axon Enterprise, Inc (NASDAQ:AXON)

DekaBank Deutsche Girozentrale decreased its stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 25.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,986 shares of the biotechnology company's stock after selling 5,826 shares during the quarter. DekaBank Deutsche Girozentrale's holdings in Axon Enterprise were worth $8,808,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in AXON. Vanguard Group Inc. increased its stake in shares of Axon Enterprise by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company's stock valued at $5,019,886,000 after purchasing an additional 275,959 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Axon Enterprise by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company's stock worth $1,095,542,000 after purchasing an additional 65,097 shares during the last quarter. Capital World Investors grew its holdings in shares of Axon Enterprise by 86.4% in the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock valued at $1,079,145,000 after acquiring an additional 841,772 shares in the last quarter. Alliancebernstein L.P. grew its holdings in Axon Enterprise by 273.8% during the fourth quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock valued at $659,128,000 after purchasing an additional 812,337 shares during the period. Finally, Norges Bank purchased a new stake in shares of Axon Enterprise during the fourth quarter worth $482,081,000. Institutional investors and hedge funds own 79.08% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on AXON. Morgan Stanley set a $885.00 target price on shares of Axon Enterprise and gave the company an "overweight" rating in a research note on Friday. Barclays increased their target price on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Bank of America raised their price objective on Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research report on Wednesday, June 4th. The Goldman Sachs Group lifted their price objective on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. Finally, Wolfe Research started coverage on Axon Enterprise in a report on Monday, July 7th. They issued an "outperform" rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $716.36.

Insider Activity at Axon Enterprise

In other news, CFO Brittany Bagley sold 3,400 shares of Axon Enterprise stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $700.00, for a total value of $2,380,000.00. Following the sale, the chief financial officer owned 131,833 shares in the company, valued at $92,283,100. This trade represents a 2.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, President Joshua Isner sold 9,905 shares of the stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $738.03, for a total transaction of $7,310,187.15. Following the completion of the sale, the president directly owned 298,809 shares in the company, valued at approximately $220,530,006.27. This represents a 3.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 44,642 shares of company stock worth $30,500,428 over the last quarter. Corporate insiders own 5.70% of the company's stock.

Axon Enterprise Price Performance

NASDAQ AXON traded down $4.39 during trading on Tuesday, hitting $745.87. 373,049 shares of the company's stock were exchanged, compared to its average volume of 704,996. The company has a market cap of $58.07 billion, a PE ratio of 180.16, a P/E/G ratio of 83.99 and a beta of 1.29. The company has a current ratio of 2.83, a quick ratio of 2.62 and a debt-to-equity ratio of 0.68. The stock's 50 day moving average price is $752.67 and its two-hundred day moving average price is $641.14. Axon Enterprise, Inc has a fifty-two week low of $279.02 and a fifty-two week high of $830.21.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, topping the consensus estimate of $1.34 by $0.07. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The business had revenue of $603.63 million during the quarter, compared to the consensus estimate of $585.67 million. During the same quarter last year, the company earned $1.15 EPS. The firm's revenue was up 31.3% compared to the same quarter last year. Research analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.